NRCT Hosts Seminar on “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment” at MHESI Fair 2025

August 16, 2025 – The National Research Council of Thailand (NRCT) organized a seminar titled “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment.” Dr. Wiparat De-ong, Executive Director of the NRCT, assigned Mrs. Mariyat Tangmitrcharoen, Director of the Division of Strategic Science Research and Innovation Data System and Management, to deliver the welcome address at Room MR202, 2nd Floor, Queen Sirikit National Convention Center.

Mrs. Mariyat Tangmitrcharoen stated that the NRCT and the Thailand Science Research and Innovation (TSRI) prioritize the development of collaborative mechanisms to propel the nation towards becoming a hub for science, research, and innovation. This seminar aims to foster the exchange of knowledge, resources, and experiences among experts from various fields. The goal is to integrate this knowledge to systematically develop cancer treatment approaches in Thailand, which will be crucial in driving medical research and innovation, enhancing the national healthcare system, and sustainably increasing survival rates for patients.

The event featured a lecture by Professor Dr. Nattiya Hirankarn of Chulalongkorn University on the “Overview of Cancer Immunotherapy Research in Thailand,” presenting advancements in immunotherapy research and future directions for developing treatments to improve efficacy and the quality of life for cancer patients.

This was followed by a panel discussion on the “Advancements of Genetic Engineered Cell Therapy,” which was divided into three topics:

1. Point of Care CD19 CAR T-cells: Towards Hospital Use by Assistant Professor Dr. Smith Kungwankiattichai of Mahidol University and Associate Professor Dr. Kitsada Wudhikan of Chulalongkorn University, who presented on the treatment of lymphoma with CAR T-cell technology, discussing the treatment principles and the importance of in-hospital manufacturing processes.

2. Progress in Multi-Center Clinical Trials of CAR T-cell Therapy for Hematologic Malignancies by Dr. Koramit Suppipat of Chulalongkorn University, who discussed the progress of multi-center CAR T-cell trials, including the preparation and logistics of apheresis products to effectively support treatment across multiple healthcare facilities.

3. PSU’s CD19 CAR T-cell Program: Recent Progress and Future Outlook by Associate Professor Dr. Jakrawadee Julamanee of Prince of Songkla University, who spoke about the CAR T-cell treatment process, clinical outcomes, observed side effects, and patient responses.

            Another panel discussion on “The Development of Biologics and Personalized Vaccines for Cancer in Thailand” covered the
            following three topics:

1. Success Story of Biologics Development and Registration for Cancer Treatment in Thailand by Associate Professor Dr. Mayuree Fuangthong of the Chulabhorn Research Institute.

2. Past, Present and Future of Biologics Security towards Commercialization in Thailand by Emeritus Professor Dr. Karnpimol Ritthidej of the Thai Red Cross Society and Dr. Trairak Pisitkun of Chulalongkorn University.

3. Towards Personalized Cancer Vaccine as Adjuvant Therapy by Dr. Trairak Pisitkun of Chulalongkorn University and Dr. Norraphat Peesirikan of the Government Pharmaceutical Organization.

   More Information: https://www.facebook.com/share/p/1C3WVi9uTj/